entertainment -WSS

entertainment

author：comprehensive 2025-10-02 18:49:02 - browse：2919

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： RaDonda Vaught links Vanderbilt hospital issues to patient death

focus

leisure time

WSS

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

As AI in medicine takes off, can 'human in the loop' prevent harm?

President Biden's budget: Here's what you might have missed

Watch the official trailer for 'Ahsoka' series

Why depression after traumatic brain injury is distinct

President Biden's budget: Here's what you might have missed

hotspot

entertainment

knowledge

Malaria cases in Florida and Texas: Here’s what you need to know

UCLA team creates talking throat patch for voice disorders

In Memoriam: Notable people who died in 2023

Digital health funding stays low as a new reality sets in

23andMe had bad news about my health. I wish a person had delivered it

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Psychedelics group wrestles with new pharma identity

Pushing for an NIH office for post

Bright Health sells Medicare Advantage business to Molina

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

hotspot

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

UCLA team creates talking throat patch for voice disorders

Amid AI frenzy, a top HHS official's quest to create safeguards

A Greenpeace activist is fined for crash

Britney Spears to release memoir, 'The Woman In Me,' later this year

focus

leisure time

knowledge

leisure time